Search Results - ima
-
21
-
22
-
23
-
24
-
25
-
26
-
27
-
28
-
29
-
30
Efficacy and Safety Results from ASC4MORE, a Randomized Study of Asciminib (ASC) Add-on to Imatinib (IMA), Continued IMA, or Switch to Nilotinib (NIL) in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Not Achieving Deep Molecular Responses (DMRs) with ≥1 Year of IMA
Published in Blood
Article -
31
-
32
-
33
-
34
-
35
-
36
-
37
-
38
-
39
-
40